Selegiline and lymphocyte superoxide dismutase activities in Parkinson's disease

Annals of Neurology

Volumn 39, Issue 3, 1996, Pages 378-381

  Kushleika, John ^a   Checkoway, Harvey ^a   Woods, James S ^a   Moon, Jai Dong ^a,b   Smith Weller, Terri ^a   Franklin, Gary M ^a   Swanson, Philip D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Chonnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROGEN PEROXIDE; REACTIVE OXYGEN METABOLITE; SELEGILINE; SUPEROXIDE DISMUTASE;

ADULT; AGED; ARTICLE; BRAIN PROTECTION; CLINICAL ARTICLE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; NERVE DEGENERATION; PARKINSON DISEASE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

ANTIPARKINSON AGENTS; BRAIN; CYTOSOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; MITOCHONDRIA; PARKINSON DISEASE; PROTEINS; SELEGILINE; SUPEROXIDE DISMUTASE;

EID: 0029925613     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410390315     Document Type: Article

References (19)

1. Jenner P. Oxidative damage in neurodegenerative disease. Lancet 1994;344;796-798
2. Martilla RJ, Lorentz H, Rinne UK. Oxygen toxicity protecting enzymes in Parkinson's disease: increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus. J Neurol Sci 1988;86:821-831
3. Saggu H, Cooksey J, Dexter D, et al. A selective increase in particulate superoxide dismutase activity in parkinsonism substantia nigra. J Neurochem 1989;53:692-697
4. Poirier J, Dea D, Baccichet A, Thiffault C. Superoxide dismutase expression in Parkinson's disease. Ann NY Acad Sci 1994;738:116-120
5. Schapira AHV, Cooper JM, Dexter D, et al. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990;54:823-827
6. Tipton KP, Singer TP. Advances in our understanding of the mechanisms of neurotoxicity of MPTP and related compounds. J Neurochem 1993;61:1191-1206
7. Jenner P, Dexter DT, Sian J, et al. oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. Ann Neurol 1992;32(suppl):S82-S87
8. Kalra J, Rajput AH, Mantha SV, Prasad K. Serum antioxidant activity in Parkinson's disease. Mol Cell Biochem 1992;110: 165-168
9. Yoshida E, Mokuno K, Aoki S, et al. Cerebrospinal fluid levels of superoxide dismutases in neurological diseases detected by sensitive enzyme immunoassays. J Neurol Sci 1994;24:25-31
10. Poirier J, Barbeau A. Erythrocyte antioxidant activity in human patients with Parkinson's disease. Neurosci Lett 1987;75:345-348
11. Martilla RJ, Viljanen M, Toivonen E, et al. Superoxide dismutase-like activity in the Parkinson's disease brain. Adv Neurol 1990;53:141-144
12. Checkoway H, Costa LG, Woods JS, et al. Peripheral blood cell activities of monoamine oxidase B and superoxide dismutase in Parkinson's disease. J Neural Transm Park Dis Dement Sect 1992;4:283-290
13. Nakano M, Kimura H, Hara M, et al. A highly sensitive method for determining both Mn- and Cu-Zn Superoxide dismutase activities in tissues and blood cells. Anal Biochem 1990;187:277-280
14. Geller BL, Winge DR. A method for distinguishing Cu,Zn-and Mn-containing superoxide dismutases. Anal Biochem 1983;128:86-92
15. Dixon WJ, ed. BMDP statistical software. Los Angeles: BMDP Statistical Software, Inc, 1992
16. Knoll J. The striatal dopamine dependency of life span in male rats: longevity study with (-)deprenyl. Mech Ageing Dev 1988;46:237-262
17. Carillo MC, Kitani K, Kanai S, et al. The ability of (-)deprenyl to increase superoxide dismutase activities in the rat is tissue and brain region specific. Life Sci 1992;50:1985-1992
18. Sandler M, Glover V, Clow A, Jarman J. Monoamine oxidase B, monoamine oxidase B inhibitors, and Parkinson's disease: a role for superoxide dismutase? Adv Neurol 1993;60:238-241
19. Rosetti ZL, Sotgiu A, Sharp DE, et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and free radicals in vitro. Biochem Pharmacol 1988;37:4573-4574